

Anaesthesia recommendations for **Gaucher disease**

Disease name: Gaucher disease

ICD 10: E75.2

Synonyms: sphingolipidosis (lysosomal storage disorder, deficiency of glucocerebrosidase)

Disease summary: Gaucher disease is one of the most common lysosomal storage disorders with defects in the enzyme glucosylceramidase (glucocerebrosidase). The disease is caused by mutations in the GBA gene on chromosome 1 (autosomal recessive) and affects both sexes. The incidence is estimated to be 1:40000 in Europe. Most commonly, the disease is differentiated into a non-neuronopathic form and a neuronopathic form. Thus, patients may present with symptoms early during childhood or later in life. Patients may develop organ damage with some manifestations in the coagulation system relevant to anaesthesia, an impaired immune competence, reduced lung function and elevated pulmonary arterial pressure in adults. A specific therapy with eliglustat may interact with perioperative medication and should be paused for 48h before surgery. Neuroaxial anaesthesia, regional-anaesthesiological nerve blocks and general anaesthesia can be performed safely in these patients with individual risk assessment.

Medicine is in progress



Perhaps new knowledge

Every patient is unique

Perhaps the diagnosis is wrong



Find more information on the disease, its centres of reference and patient organisations on Orphanet: www.orpha.net

Typical surgery

Patients with Gaucher disease may present for all types of surgery. However, as the disease can lead to splenomegaly and also was described to be associated with femoral head necrosis and bone pathology, spleen extirpation and musculoskeletal surgery are typical for these patients.

Type of anaesthesia

The anaesthesiologically relevant aspects in Gaucher disease are related to

- Haematopoietic system with anaemia, thrombocytopenia, impaired coagulation capacity and leucopenia with impaired immune competence,
- Impaired lung function,
- Impaired CNS function including epilepsy and dysphagia,
- Pulmonary arterial hypertension in adult patients, e.g. receiving enzyme replacement therapy.

Based on current knowledge, all types of anaesthesia can be performed safely. The choice of anaesthesia should depend on the specific manifestations of the individual patients. If possible, regional anaesthesia should be preferred especially in patients with pulmonary complications but should be evaluated carefully against the background of potential coagulopathy. In general anaesthesia, volatile and intravenous hypnotics can be administered. In patients with a history of coagulopathy or abnormal laboratory coagulation tests, neuroaxial anaesthesia should be avoided.

Necessary additional pre-operative testing (beside standard care)

Standard preoperative measures to evaluate patients and an interdisciplinary case review (e.g. involving surgeon, anaesthesiologist and haematologist) will allow individualised decision making for additional diagnostic testing. This should also focus on a detailed patient history of clinical signs of bleeding (e.g. gum bleeding, heavy menstruation bleeding, spontaneous haematoma) and obtaining blood tests. Standard coagulation tests (partial thromboplastin time, INR, blood count) can be expanded to identify impaired haemostasis like thrombocytopenia (thromboelastography) or deficiency of coagulation factors.

Furthermore, the pulmonary and cardiovascular capacity should be evaluated to assess metabolic equivalents and signs for cardiac decompensation (as described in guidelines for evaluation of adults before non-cardiac surgery). In specific cases, ECG and transthoracic sonography should be performed to determine ejection fraction, valvular defects (like tricuspid insufficiency) and elevated pulmonary-arterial pressure. Specific attention should also be paid to the medication intake of patients as some patients may be treated with eliglustat (Cerdelga®) which may interact with drugs during anaesthesia.

Particular preparation for airway management

There is currently no evidence of specific preparations necessary in these patients.

Particular preparation for transfusion or administration of blood products

Standard preparation for scheduled surgery is advisable. However, in patients with clinical evidence of coagulopathy or those with thrombocytopenia, preoperative measures are to be discussed interdisciplinary with surgeons, anaesthesiologists and patients. For patients with an increased risk of bleeding complications, blood products should be prepared.

Particular preparation for anticoagulation

Gaucher disease seems not to be associated with thrombotic events but has some risks for increased bleeding. In patients with clinical evidence of coagulopathy or those with thrombocytopenia, an individualised risk assessment is necessary. If there is an increased risk for perioperative thrombotic events, anticoagulation treatment is indicated as standard of care.

Particular precautions for positioning, transportation and mobilisation

Gaucher disease is associated with musculoskeletal deformities that will be evaluated in preoperative assessment. Based on that, individual measures are to be planned. However, there are no specific points to consider in these patients according to current evidence.

Interactions of chronic disease and anaesthesia medications

Some patients will be treated with specific agents approved for Gaucher disease. Specific caution is necessary in patients receiving eliglustat (Cerdelga®), a drug acting as highly specific inhibitor of enzymes for glucocerebrosidase syntheses. This substrate-reducing therapy may interfere with perioperative drug therapy. Eliglustat is metabolised strongly by hepatic CYP2D6 enzymes and to a lesser extent by CYP3A4. Thus, all inhibitors of these pathways may increase the toxicity of eliglustat and should be avoided. Indeed, not only CYP2D6 inhibitors but also inducers or substrates of cytochrome P450 (CYP) enzymes may affect the metabolism of the drug. For concomitant treatment, data bases for drug interaction may be a source of further information as are clinical pharmacologists.

For perioperative use, this interaction may affect the following drugs (examples):

- 5HT3-antagonists (ondansetron),
- Beta blockers,
- Opioids like codeine and tramadol,
- Anti-infectives (rifampicin, erythromycin, voriconazole, posaconazole, clarithromycin, ciprofloxacin etc.).

Interaction with eliglustat may cause significant adverse events, with long-QT-syndrome and sequelae like Torsade-de-pointes-tachycardia.

Due to the circulating half-life of eliglustat of 7-9 hours, the drug should be stopped about 48 hours before surgery.

There are no specific anaesthetic implications for patients treated with enzyme replacement therapy.

Anaesthetic procedure

Gaucher disease does not alter standard anaesthetic procedures. In patients with coagulopathy, haemostasis should be optimised preoperatively.

Particular or additional monitoring

The choice of monitoring and additional measures perioperatively should be adapted according to the patient's individual conditions.

Possible complications

Perioperative bleeding complications should be anticipated. In patients with concomitant use of eligustat, the risk for cardiac events may be increased. In patients with Gaucher disease, there is an increased risk of postoperative infections, thus, antibiotic prophylaxis should be administered.

Post-operative care

The choice of postoperative care should be adapted to the patient's individual condition. In patients with high risk of bleeding, post-operative pain management should evaluate the choice of drugs used including increased risk related to NSAIDs use.

Disease-related acute problems and effect on anaesthesia and recovery

No specific points to consider.

Ambulatory anaesthesia

The choice between ambulatory versus in-hospital care should be adapted to the patient's individual conditions.

Obstetrical anaesthesia

The choice of anaesthesia in obstetric surgery and to support birth follows an individual risk assessment. Due to potential interactions with the coagulation system and with physiologic changes in pregnancy, blood test results should be available to assess the current status of platelet count and coagulation parameters. There is some evidence in literature that neuroaxial anaesthesia like epidural anaesthesia or spinal anaesthesia are possible modalities during birth. The risk of perioperative bleeding, though, could be increased.

References

1. Nagral A. Gaucher disease. J Clin Exp Hepatol 2014;4:37–50
2. Ioscovich A, Briskin A, Abrahamov A, Halpern S, Zimran A, Elstein D. Uncomplicated outcome after anaesthesia for pediatric patients with Gaucher disease. Can J Anaesth 2005;52:845–847
3. German Guideline 2006:
<https://www.ggd-ev.de/wp-content/uploads/mggaucher-22-12-2007.pdf>
4. Ioscovich A, Elstein Y, Halpern S, Vatashsky E, Grisaru-Granovsky S, Elstein D. Anesthesia for obstetric patients with Gaucher disease: survey and review. Int J Obstet Anesth 2004;13:244–250
5. Pinto J, Segura E, Ribeiro S, Amaral R. [Anesthetic management in a pregnant woman with type 1 Gaucher disease]. Rev Esp Anesthesiol Reanim 2010;57:243–244
6. For Eliglustat therapy:
https://www.g-ba.de/downloads/92-975-826/2015-03-30_M4A_Eliglustat.pdf [German] and
EPAR of EMEA (<http://www.ema.europa.eu>)
https://ec.europa.eu/health/documents/community-register/2015/20150119130463/anx_130463_de.pdf [GERMAN].

Date last modified: **November 2017**

This recommendation was prepared by:

Author

Sascha Tafelski, Anaesthesiologist, University hospital Campus Virchow Klinikum and Campus Charité Mitte, Berlin, Germany
Sascha.Tafelski@charite.de

Disclosure The author has no financial or other competing interest to disclose. This recommendation was unfunded.

This recommendation was reviewed by:

Reviewers

Olga Levchenko, Anaesthesiologist, National Research Center for Hematology
Moscow, Russian Federation, Russia
levchenkokp@rambler.ru

Jeff Szer, Disease Group Lead: Non-malignant haematology, Parkville Integrated Haematology Service, The Royal Melbourne Hospital, Melbourne, Australia
jeff.szer@mh.org.au

Disclosure The reviewers have no financial or other competing interest to disclose.
